Randomized Study of Fluoxetine in Children and Adolescents With Autism
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 3
研究概览
简要总结
OBJECTIVES: I. Evaluate the efficacy of fluoxetine on social and language deficits, global severity and compulsive dimensions of children and adolescents with autism.
II. Assess the effectiveness of this treatment regimen on neurocognitive deficits in this patient population.
III. Compare the baseline compulsive severity and treatment outcome in these patients.
详细描述
PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, crossover study. All patients receive oral placebo daily during week 0.
Patients are randomized to receive either oral fluoxetine or oral placebo daily on weeks 1-8. Patients then crossover to receive treatment on the other arm during weeks 12-20.
Completion date provided represents the completion date of the grant per OOPD records
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 5 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PROTOCOL ENTRY CRITERIA:
- •-Disease Characteristics--
- •Meets diagnostic criteria for autism
- •-Prior/Concurrent Therapy--
- •At least 3 months since prior electroconvulsive therapy
- •At least 1 month since prior investigational drugs or treatment with any drug known to cause major organ toxicity
- •At least 2 weeks since prior monoamine oxidase inhibitors
- •At least 6 weeks since prior long acting phenothiazines
- •At least 1 week since prior other psychotropic drugs
- •No prior fluoxetine of 20 mg/day for 6 weeks
- •At least 6 weeks since prior fluoxetine
- •No concurrent use of terfenadine (Seldane) or astemizole (Hismanal)
- •No concurrent electroconvulsive therapy or other psychotropic drugs (unless otherwise permitted)
- •Prior participation in another serotonin reuptake inhibitor trial allowed
- •-Patient Characteristics--
- •Hematopoietic: No significant hematopoietic disease
- •Hepatic: No prior or concurrent liver disease
- •Renal: No prior or concurrent kidney disease
- •Cardiovascular:
- •No significant cardiovascular disease
- •No abnormal EKG
- •Neurological:
- •No prior seizure disorder or high risk development of seizures
- •No prior cerebrovascular disease
- •No prior brain trauma
- •Not pregnant or nursing
- •Negative pregnancy test
- •No unstable major medical illness or systemic disease
- •No moderate or severe mental retardation and motor deficits (IQ less than 50)
- •No family history of bipolar disorder
- •No prior or concurrent other mental disorders (e.g., schizophrenia, schizoaffective, organic, or bipolar disorders)
- •No significant autoaggressive behavior or serious suicidal risk
- •No prior or concurrent gastrointestinal conditions
- •No unstable endocrine disease (e.g., hypo or hyperthyroidism)
- •No prior or concurrent malignancy
- •Must be able to tolerate tapering of psychoactive medication
- •No history of hypersensitivity or severe side effects to fluoxetine or other serotonin reuptake inhibitors
- •No history of severe personality disorder or noncompliance
排除标准
- 未提供